Mavenclad®

DRUG4 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions

Multiple Sclerosis

Phase 4

Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

CompletedNCT03364036

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2018-05-28End: 2022-02-21Updated: 2023-03-16

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

CompletedNCT03369665

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2018-06-20End: 2021-11-12Updated: 2023-09-14

Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

CompletedNCT04776213

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2021-02-23End: 2023-06-20Updated: 2024-05-28

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

CompletedNCT04783935

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2021-03-10End: 2023-09-21Updated: 2025-01-22

Related Papers

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

2026-08-04

Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.

2026-03-10

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

Therapeutic Advances in Neurological Disorders2025-07-314 citations

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Frontiers in Immunology2025-02-037 citations

Abstracts from the 38th Annual Meeting of the Consortium of Multiple Sclerosis Centers: May 29-June 1, 2024 · Nashville, Tennessee

International Journal of MS Care2024-05-012 citations

Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006)

Neurology2023-04-253 citations

Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018)

Neurology2023-04-251 citations

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets

Neurology Neuroimmunology & Neuroinflammation2022-11-2137 citations

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation2022-06-1431 citations

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.

2021-11-0914 citations

Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis (1921)

Neurology2021-04-133 citations

Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis (1925)

Neurology2021-04-132 citations

A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487)

Neurology2020-04-142 citations